NCT03174171View on ClinicalTrials.gov

Open-label Study on Treatment of Primary Aldosteronism With Everolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 22, 2017

Primary Completion Date

June 25, 2018

Study Completion Date

June 25, 2018

Conditions
Primary Aldosteronism
Interventions
DRUG

Everolimus 0.75 mg

Everolimus 0.75 mg b.i.d. orally for 14 days.

Trial Locations (1)

4031

University Hospital Basel, Basel

All Listed Sponsors
lead

University Hospital, Basel, Switzerland

OTHER

NCT03174171 - Open-label Study on Treatment of Primary Aldosteronism With Everolimus | Biotech Hunter | Biotech Hunter